Novartis AG NVS

Novartis AG is an international pharmaceutical company that engages in research, development, and production of innovative medicines for the treatment of various diseases. The company was founded in 1996 as a result of the merger of Ciba-Geigy and Sandoz and is headquartered in Basel, Switzerland.

Novartis operates in more than 155 countries worldwide and has over 100,000 employees. The company is one of the leaders in the pharmaceutical industry, specializing in the development and production of drugs for the treatment of cancer, cardiovascular diseases, neurological disorders, respiratory diseases, allergies, and other serious illnesses.

Novartis' portfolio includes more than 750 products, including well-known brands such as Gilenya, Lucentis, Sandostatin, Tasigna, and others. The company invests significant resources in research and development of new drugs to improve the lives and health of patients.

Novartis is also actively working on sustainable development and social responsibility. The company aims to become carbon neutral by 2025 and reduce its impact on the environment. It also implements programs to support communities and patients around the world.

In recent years, Novartis has made several significant acquisitions, including Alcon, AveXis, and The Medicines Company. These acquisitions have helped to expand the company's portfolio and strengthen its position as a leading pharmaceutical company.

In conclusion, Novartis AG is an international pharmaceutical company with a strong commitment to research and development, sustainability, and social responsibility. Its products and services have a significant impact on the healthcare industry and the lives of millions of people around the world.